Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Amicus Therapeutics

5 clinical trials · 5 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Amicus Therapeutics

RECRUITINGPhase 3NCT06904261

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to \< 12 years of age with...

Sponsor: Amicus TherapeuticsEnrolling: 89 locations
Fabry Disease
RECRUITINGNCT04252066

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and...

This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy...

Sponsor: Amicus TherapeuticsEnrolling: 201 location
Fabry Disease
RECRUITINGNCT06906367

A Study of Patients With Fabry Disease (US Specific)

This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease,...

Sponsor: Amicus TherapeuticsEnrolling: 4507 locations
Fabry Disease
RECRUITINGNCT06121011

A Global Prospective Observational Registry of Patients With Pompe Disease

This is a global, multicenter, prospective, observational registry of patients with Pompe disease, including those with late-onset pompe disease (LOPD) and infantile-onset pompe...

Sponsor: Amicus TherapeuticsEnrolling: 50020 locations
Pompe Disease
RECRUITINGPhase 3NCT04808505

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects...

This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and...

Sponsor: Amicus TherapeuticsEnrolling: 3614 locations
Glycogen Storage Disease Type II Infantile Onset